A5091222778- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Use and Resistance
- Pneumocystis jirovecii pneumonia detection and treatment
- Drug-Induced Adverse Reactions
- Bacterial Identification and Susceptibility Testing
- Service-Learning and Community Engagement
- Evaluation and Performance Assessment
- COVID-19 and healthcare impacts
- Pharmacovigilance and Adverse Drug Reactions
- Neutropenia and Cancer Infections
- Antimicrobial Resistance in Staphylococcus
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Antifungal resistance and susceptibility
- Nursing Education, Practice, and Leadership
- Poisoning and overdose treatments
- Acne and Rosacea Treatments and Effects
- Anesthesia and Neurotoxicity Research
- Women's cancer prevention and management
- Animal testing and alternatives
- Hearing, Cochlea, Tinnitus, Genetics
- Cerebral Venous Sinus Thrombosis
- Pharmaceutical Practices and Patient Outcomes
- Blood disorders and treatments
Brooklyn Hospital Center
2020-2025
Touro College
2022-2024
Long Island University
2021
This study was performed to compare clinical characteristics and outcomes between patients with bloodstream infections (BSIs) caused by Candida auris those BSIs other spp.A multicenter retrospective case-control at 3 hospitals in Brooklyn, New York, 2016 2020. The analysis included ≥18 years of age who had a positive blood culture for any spp. were treated empirically an echinocandin. primary outcome the 30-day mortality rate. Secondary 14-day failure, 90-day rate, 60-day microbiologic...
Abstract Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen Klebsiella pneumoniae, and 30-day survival 74%. Absence of recurrence resolution signs symptoms infection were 91% 57%, respectively. ERV well-tolerated, with adverse events leading to drug discontinuation one patient.
Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates carbapenem resistant (CRAB). Infections primarily pulmonary (58.3%), and most received combination therapy (84.4%). The median (IQR) ERV duration was 6.9 days (5.1 to 11.1). Thirty-day mortality 23.9% in the cohort 21.9% CRAB patients. One patient experienced an ERV-possible adverse event.
ABSTRACT Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical microbiological outcomes addition associated adverse effects of eravacycline used hospitals. Real-world, observational involving patients receiving ≥72 h at 19 medical centers located all 5 regions United States between October 2018 August 2022. The primary outcome was success, defined as survival absence recurrence 30 days from end therapy...
Abstract Background Carbapenem-resistant Enterobacterales (CRE) are a major public health threat due to increasing prevalence and limited effective treatment options. Meropenem/vaborbactam (M/V) is beta-lactam/beta-lactamase inhibitor agent designed treat CRE. There paucity of data related patient characteristics associated outcomes with the utilization M/V in pneumonia The objective this study was describe real-world experience setting. Methods This retrospective, observational,...
This self-guided, online program is designed for participants to increase the knowledge and skills necessary provide patient-centric care develop system specific crisis pandemic management capability.
As of December 2020, there were over 450,000 confirmed coronavirus disease 2019 (COVID-19) cases in New York City (NYC) with approximately 25,000 deaths. Previous literature identified advanced age, higher severity illness, elevated inflammatory biomarkers, acute organ dysfunction, comorbidities, and presentation from long-term care facility as risk factors for mortality patients Wuhan, China, the United States. Additional studies conducted NYC are warranted to confirm these findings. The...
Since the issuance of emergency use authorization (EUA) 3 coronavirus disease 2019 (COVID-19) vaccines, there have been over 180 million individuals fully vaccinated in United States (US). With increasing administration COVID-19 vaccinations, 550,000 adverse events reported Vaccine Adverse Event Reporting System (VAERS) with approximately 230,000 experienced after receipt Pfizer-BioNTech as September 23 rd 2021. Audio-vestibular symptoms (including Sudden Sensorineural Hearing Loss (SSNHL))...
Aminoglycosides possess activity against aerobic gram-negative organisms and are often used in combination with beta-lactam antibiotics. Previous studies evaluating therapy bacteremia have not shown clear benefits, however antimicrobial resistance was prevalent these studies. Our objective is to elucidate potential benefits of adding a single dose an aminoglycoside patients bacteremia.
Abstract Background Eravacycline (ERV) is FDA-approved for the treatment of complicated intra-abdominal infections, but there limited experience non-FDA approved indications. Methods We present five cases that utilized ERV bacteremia. Results Patient 1 in septic shock (SS) started on vancomycin (VAN) and ceftazidime-avibactam (CZA). Blood culture (BC) finalized to E. coli regimen narrowed CZA. On day 9, gram-positive cocci chains BC grew VAN was added. VRE faecium modified 12. Repeat 15 no...
Introduction: There are currently limited published data for a pharmacist-led multidrug-resistant (MDR) culture follow-up program through collaborative drug therapy management (CDTM) agreement in the emergency department (ED). Objective: The objective of this study was to assess impact MDR microbiology results on ED revisit rate. Methods: A single-center quasi-experimental retrospective conducted comparing outcomes before (December 2017 March 2019) and after (April 2019 July 2020)...
To assess the impact of legislative visits on student pharmacists' perceptions advocacy by comparing changes in Political Skill Inventory (PSI), skills, and responsibility scores before after a visit.
To improve the student pharmacists' knowledge, attitudes, skills, and competence in advocacy for pharmacy profession.
Abstract Background Carbapenem-resistant Enterobacterales (CRE) are a significant public health threat. Ceftazidime-avibactam (CZA) retains activity against most carbapenemase-producing CRE and demonstrates favorable outcomes compared to historically best available therapy. While early initiation of effective therapy is critical in serious infections, the impact time CZA on infection-related has yet be assessed. Aim: evaluate clinical patients with infections receiving vs. late as first...
Abstract Background Eravacycline (ERV) is Food and Drug Administration approved in patients for the treatment of adults complicated intra-abdominal infections 2018. Real-world data regarding indications ERV use are limited. We evaluated clinical/safety outcomes treated with FDA non-FDA indications. Methods Multicenter, retrospective, observational study from September 2018 to June 2020. Adult ³ 72 hours were included. The primary outcome was 30-day survival. Secondary included a lack...
Abstract Background As of May 2020, there were over 190,000 confirmed COVID-19 cases in New York City (NYC) with approximately 13,000 deaths. Previously published literature identified risk factors (advanced age, higher severity illness and elevated d-dimer) for mortality a cohort patients from Wuhan, China mechanical ventilation case series NYC. Another NYC evaluated clinical outcomes only. There are limited studies assessing characteristics, The objective this study was to assess the...
Abstract Background Infections caused by multidrug-resistant (MDR) bacteria are an increasingly common public health threat associated with worse outcomes in immunocompromised patients. Eravacycline (ERV) has potent in-vitro activity against MDR Gram-negative and Gram-positive demonstrated non-inferiority to meropenem the phase III IGNITE4 trial; however, trial excluded We aimed evaluate clinical safety endpoints of patients receiving ERV as definitive therapy. Methods Multicenter,...
Abstract Background Eravacycline (ERV) is approved in the United States (US) for treatment of complicated intra-abdominal infections adults. We aimed to evaluate independent predictors clinical success patients treated with ERV various infections. Methods Multicenter, retrospective, observational study conducted from September, 2018 April, 2021. included adults ≥ 72hours. Clinical was defined as 30-day survival, lack infection-recurrence, and resolution infection signs/symptoms. All outcomes...
Abstract Background The emergence of Candida auris as a global pathogen has been described serious threat by the CDC. It caused outbreaks in healthcare settings it is transmissible between patients. risk factors for candidemia C. may be different than other spp. Methods We performed multicenter, retrospective case-control study at three hospitals Brooklyn, New York 2016 and 2020. Patients with least one positive blood culture spp who were started empirically on an antifungal within 24 hours...